StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) company profile

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

About Exelixis

Biological Products, (No Diagnostic Substances), SIC 2836

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted medicines for various forms of cancer. Its commercial portfolio features cabozantinib formulations, primarily marketed as CABOMETYX tablets and COMETRIQ capsules, alongside cobimetinib (COTELLIC) and esaxerenone (MINNEBRO). The company focuses on developing small molecules and biotherapeutics, such as antibody-drug conjugates, to treat indications including advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors. Its offerings serve physicians, healthcare providers, and cancer patients, while its clinical pipeline features investigational candidates like zanzalintinib across multiple oncology settings.

The company markets its products in the United States and distributes cabozantinib internationally across 68 other countries through regional collaboration partners, including Ipsen outside the U.S. and Japan, and Takeda within Japan. Regulatory approvals span major geographic markets such as the European Economic Area, the United Kingdom, Japan, Canada, Brazil, Taiwan, South Korea, Australia, and Hong Kong. The provided text does not state the company's headquarters location.

Summary of the business section of Exelixis's latest annual report, written by StockData.

Company profile

Company

Legal name
Exelixis, Inc.
Founded
1994
Headquarters
Alameda, CA
Address
1851 Harbor Bay Parkway 94502
Phone
(650) 837-7000
Employees
1,077, Jan 2, 2026
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
January 1
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
EXEL
Exchange
Nasdaq
IPO date
Apr 11, 2000
Shares outstanding
244M, Oct 19, 2026
Public float
$9.40B, Jul 4, 2025
Filer category
Large accelerated filer
SEC CIK
939767
CUSIP
30161Q104
ISIN
US30161Q1040
FIGI
BBG000BQ4WF8
Share class FIGI
BBG001SD42W4
LEI
254900PJQB59O2O95R37
EIN
04-3257395

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael MorrisseyPresident and CEO, Director3,384,063
Dana AftabEVP, Research and Development600,576
Patrick J. HaleyEVP, Commercial357,638
Brenda HeftiSVP and General Counsel112,289
Christopher J. SennerEVP and CFO955,040
Amy C. PetersonEVP Prod Dev & Med Aff & CMO538,169
Jeffrey HessekielEVP & General Counsel694,395
Mary C. BeckerleDirector16,079
Sue Gail EckhardtDirector16,079
Jack L. WyszomierskiDirector284,384
Julie SmithDirector28,957
George PosteDirector127,199
Stelios PapadopoulosDirector1,197,595
Maria C. FreireDirector109,186
Tomas J. HeymanDirector50,649
David Edward JohnsonDirector1,543,906
Partners LP CaliganDirector1,571,438
Bob OliverDirector29,487

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$33.24M$55.13M$9.09M$217$125
FY2024$12.73M$39.39M$4.12M$200$122
FY2023$16.42M$31.70M$5.51M$141$121
FY2022$16.88M$16.02M$5.15M$94$116
FY2021$7.53M$15.30M$3.51M$107$129
FY2020$2.35M$18.57M$1.24M$118$129

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Michael M. Morrissey
President and Chief Executive Officer
$1.31M$30.54M$1.38M$11.00K$33.24M+161%
Christopher J. Senner
Executive Vice President and Chief Financial Officer
$822.82K$9.34M$470.78K$11.00K$10.65M+128%
Dana T. Aftab
Executive Vice President, Research and Development
$659.06K$9.48M$397.25K$11.00K$10.55M+192%
Patrick J. Haley
Executive Vice President, Commercial
$621.32K$8.06M$327.30K$11.00K$9.02M–
Brenda J. Hefti
Senior Vice President and General Counsel
$454.55K$3.45M$286.75K$11.00K$4.20M–
Jeffrey J. Hessekiel
Former Executive Vice President, General Counsel
$672.37K$8.31M–$11.00K$8.99M+141%
Amy C. Peterson
Former Executive Vice President, Medical Affairs, and Chief Medical Officer
$614.50K$8.44M–$2.09M$11.15M+151%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 1,077 employees, representing a 6.10% decrease in our employee workforce as compared to December 31, 2024.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?